Print

RedHill Biopharma Ltd. Announces a Successful Pivotal Bioequivalence Trial with RHB-103 for the Treatment of Migraine  
5/29/2012 9:57:01 AM

TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE: RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development of late clinical-stage (Phase II/III), patent protected, new formulations and combinations of existing drugs, announces positive results in a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of Rizatriptan for the treatment of acute migraine. RedHill has exclusive world-wide rights and is developing RHB-103 with its Canadian co-development partner IntelGenx, Corp. (TSX: IGX)(OTCBB: IGXT).
//-->